A detailed history of Fox Run Management, L.L.C. transactions in Altimmune, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 12,905 shares of ALT stock, worth $82,979. This represents 0.02% of its overall portfolio holdings.

Number of Shares
12,905
Holding current value
$82,979
% of portfolio
0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$6.02 - $9.85 $77,688 - $127,114
12,905 New
12,905 $93,000
Q1 2023

May 12, 2023

BUY
$4.19 - $16.83 $127,522 - $512,221
30,435 New
30,435 $128,000
Q3 2022

Nov 07, 2022

BUY
$10.67 - $22.41 $136,821 - $287,363
12,823 New
12,823 $164,000
Q4 2021

Feb 09, 2022

SELL
$8.69 - $12.48 $97,023 - $139,339
-11,165 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$8.43 - $16.81 $94,120 - $187,683
11,165 New
11,165 $126,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $315M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.